ロード中...
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma
The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset of resistance in the majority of patients. Here we show that treatment of NRAS-mutant melanoma cell lin...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4211982/ https://ncbi.nlm.nih.gov/pubmed/25130256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12303 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|